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Introduction 
Wilson’s disease (WD) is an autosomal recessive disorder of copper metabolism which is 
caused by failure of biliary excretion of excess copper. The excess copper toxicity results 
in damage to the organs, primarily brain and/or liver 1.  This disorder is progressive and 
ultimately fatal if not recognized and treated.  
There are a variety of agents used to remove copper from the body. In 1956, J M Walshe 
introduced D-penicillamine as a copper chelating agent that revolutionized the treatment 
of WD 2.  Although penicillamine is a good chelator of copper, it has a life threatening 
side effect profile and there is a high chance of neurological symptoms especially in 
neurological WD patients 3, 4, 5.  
Zinc treatment for WD was reported in 1961 by Schouwink 6. Zinc works by inducing 
intestinal metallothionein which preferentially binds to ingested copper within the 
duodenal enterocyte and copper is shed in the intestine during normal enterocyte 
turnover. Zinc also induces copper binding metallothionein in hepatocytes, thereby 
reducing the damaging effects of free copper 7. Zinc has no major side effects other than 
gastric irritation especially with its sulfate salt.  
Zinc monotherapy is presently recommended only for presymptomatic patients or those 
on maintenance therapy 8.  There are at present no recommendations for the use of zinc 
monotherapy in patients of WD with hepatic and /or neurological symptoms.  
In our centre, the majority of WD patients cannot continue long term penicillamine due to 
its prohibitive cost. The aim of our study was to evaluate the efficacy of initial chelation 
with penicillamine followed by zinc monotherapy. We included symptomatic patients of 
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WD who were initiated on penicillamine but were unable to continue either due to 
financial constraints or the development of serious adverse effects of penicillamine.  
 
Our study sets the platform for the search for an alternative safe, effective and affordable 
agent for the treatment of WD.  
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Review of Literature 
Introduction: 
Wilson’s disease is a rare autosomal recessive genetic disorder of copper metabolism, 
which is characterised by hepatic and neurological disease. This disease was first 
described as a syndrome by Kinnier Wilson in 1912 as a “progressive lenticular 
degeneration”, a familial lethal neurological disease accompanied by chronic liver 
disease leading to cirrhosis 9. The disease aﬀects between one in 30 000 to one in 
100,000 individuals. Most symptoms appear in the second and third decades of life. In 
affected individuals, there is accumulation of excess copper in the liver caused by 
reduced excretion of copper in bile. The great danger is that Wilson’s disease is 
progressive, can remain undiagnosed, and is fatal if not treated. 
 
 
Molecular pathogenesis: 
In 1993 the abnormal gene for WD was identified and pattern was found to be autosomal 
recessive 10,11,12. The gene ATB7B on chromosome 13q14, encodes a transmembrane 
protein ATPase (ATP7B), which functions as a copper-dependent P-type ATPase. The 
ATP7B transporter has dual synthetic and excretory roles, functioning in the transport of 
copper into the trans-Golgi compartment, for incorporation into the plasma protein 
ceruloplasmin, and into the bile, for excretion of excess stores. Defective ATP7B 
function results in hepatic copper accumulation, which leads to the hepatic and 
neurological features of Wilson’s disease.  
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Mutation of the protein ATP7B can interrupt its normal cellular processing. The most 
common ATP7B mutation found in patients of European origin is the histidine to 
glutamate substitution at aminoacid 1069 (H1069Q). In the hepatocytes of patients with 
Wilson’s disease homozygous for H1069Q, ATP7B was mislocalised to the endoplasmic 
reticulum consistent with a failure of the mutant protein to undergo normal traﬃcking to 
its usual resident position in the trans-Golgi network. Dietary copper is absorbed in the 
stomach and duodenum and transported via the portal vein to the liver, which is the main 
organ responsible for copper homoeostasis. Copper is taken up into the hepatocyte via 
copper transporter 1 (CTR1) on the sinusoidal aspect of the hepatocyte. In the cytoplasm, 
glutathione and metallothionein proteins are important scavengers, protecting the cell 
from copper’s toxic eﬀects. A specific copper chaperone, ATOX1, delivers copper to the 
Wilson’s disease protein, ATP7B, by copper-dependent protein-protein interaction. 
ATP7B brings about transport of copper into the trans-Golgi and holo-ceruloplasmin and, 
under conditions of copper loading, into vesicles for export of copper into bile 7. 
 
The biliary excretion process includes another protein, COMMD1 (originally called 
MURR1), which interacts directly with ATP7B. Mutation of COMMD1 causes the 
copper toxicosis of Bedlington terriers—an autosomal recessive disorder that involves 
hepatic copper overload and deficient biliary copper excretion.  However, sequencing and 
haplotype analysis reported no evidence to implicate the COMMD1 protein in copper-
storage disorders of undefined aetiology in human beings 7. 
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  Figure 1: pathways of copper metabolism in the hepatocyte 
  Cu=copper. CTR1=copper transporter 1. MT=metallothioneins.  
  GSH=glutathione. Cp=caeruloplasmin. 
Mutation Analysis: 
More than 260 reported mutations in the ATP7B gene have been detected in many 
different populations by single-strand conformation polymorphism analysis or by 
sequencing of each of the 21 exons 11,13,14. These mutations are recorded in the WD 
Mutation Database 15. High-throughput methods are making mutation analysis more 
feasible for this disease, as for many others. Mutation analysis can be carried out with 
approaches such as denaturing high-performance liquid chromatography 16 or by high-
throughput sequencing of either selected or all exons of the gene.  
The majority of mutations identified to date in ATP7B are missense mutations (57%). 
Small deletions and insertion (28%), nonsense (7%), and splice site (8%) mutations occur 
throughout the gene 15. Various ethnic groups have different specific mutations. The 
 12
common histidine1069glutamine (His1069Gln) mutation 11 is present at least in the 
heterozygous state in 35% to 75% of Europeans with Wilson disease; the higher rate is 
relevant only for Eastern Europe 17. Exon 8 of the gene is particularly rich in mutations in 
European populations; depending on the age of onset, at least one mutation can be 
identified in exon 8 in about 50% to 60% of patients 18. The mutation arginine778leucine 
is common in Chinese populations 13. Because no mutation is present in high frequency 
in Japanese and Mediterranean populations, mutation detection is more challenging in 
such populations. In some populations that have ethnic homogeneity or in which the 
spectrum of mutations is established, testing strategies can identify the mutations in more 
than 90% of patients, as in Sardinians, among whom Wilson disease occurs with a 
frequency of 1 in 7000 live births 19. If the patient is clinically normal, has only slight 
signs of the disease, or has a late age of onset, that patient could actually be a 
heterozygote. However, up to now, heterozygotes have not been known to become 
clinically affected or to require treatment. 
No individual biochemical test is reliable for the identification of patients. In some cases, 
even all combinations of tests prove inadequate for a diagnosis. The use of molecular 
tests in patients with any clinical symptoms of the disease may become routine in the 
near future and is already feasible in some populations. 
Mutation analysis – Indian perspective: 
The spectrum of ATP 7 B mutations in patients with WD, mostly from three southern 
Indian states and their family members were studied. The spectrum of ATP 7 B mutations 
were described including 11 novel mutations in Indian WD patients and were 
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documented lack of single dominant mutation. Identical WD phenotype among siblings 
in 6 of 8 families with > 1 child affected by WD suggests that factors other than ATP 7 B 
mutation influence WD phenotype 20. 
 
In eastern India, WD patients from 109 unrelated families and their first-degree relatives 
comprising 400 individuals were enrolled to study the spectrum of ATP 7B mutations. In 
addition to previous reports, eight mutations including three novel (c.3412 + 1G > A, 
c.1771 G > A, c.3091 A > G) variants were identified. 17 mutations were identified in 
eastern India including five common mutations that account for 44% of patients. 
Comparative study on WD mutations between different regions of India suggests high 
genetic heterogeneity and the absence of a single or a limited number of common founder 
mutations. Genotype–phenotype correlation revealed that no particular phenotype could 
be assigned to a particular mutation and even same set of mutations in different patients 
showed different phenotypes 21.  
 
In Northwest states of India there was absence of common mutations H1069Q, R778W 
and R778L mutations in WD patients. R778W and I1102T mutations were present in 
36% of WD patients 22. The copper ATPase activity in WD patients was significantly 
reduced (50%) than that of control individuals. No significant difference was observed in 
copper stimulated ATPase activity between homozygous (R778W/R778W, 
I1102T/I1102T) and compound heterozygous (R778W/unknown mutation, 
I1102T/unknown mutation) WD patients 22. 
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Pathology: 
In the early stages before cirrhosis develops, histologic findings in the liver consist of 
steatosis, focal necrosis, glycogenated nuclei in hepatocytes, and sometimes apoptotic 
bodies 23. As parenchymal damage progresses, possibly through repeated episodes of 
lobular necrosis, periportal fibrosis develops. Cirrhosis is usually macronodular but may 
be micronodular. 
Early in the course of WD, hepatocellular copper is bound mainly to metallothionein and 
distributed diffusely in the cytoplasm of hepatocytes; therefore, results of histochemical 
stains for copper are negative. As the disease progresses, copper exceeds the capacity of 
metallothionein and is deposited in lysosomes. These lysosomal aggregates of copper can 
be detected by special staining techniques for copper or copper-binding protein (such as 
rubeanic acid or orcein). Copper is usually distributed throughout the hepatic lobule or 
nodule, but in the cirrhotic liver, some areas may have no stainable copper at all. If the 
clinical presentation mimics that of autoimmune hepatitis, liver biopsy specimens reveal 
classic histologic features of chronic hepatitis, such as interface hepatitis 24. Inflammation 
may be severe. Results of Mallory staining for hyalin may be positive, and hepatocellular 
copper accumulation may be detected in upto 50% of biopsy specimens 25. In patients 
who present with fulminant hepatic failure, liver biopsy confirms preexisting liver 
disease; cirrhosis may be present; and parenchymal copper is located mainly in Kupffer 
cells rather than in hepatocytes. 
Changes in hepatocellular mitochondria, identified with electron microscopy, are an 
important feature in Wilson disease 24. The mitochondria vary in size; the numbers of 
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dense bodies in mitochondria may be increased. The most striking change is dilatation of 
the tips of the mitochondrial cristae as a result of separation of the inner and outer 
membranes of the cristae, so that the intercristal space is widened to an irregular cystic 
shape. The crista resembles a tennis racquet if only the tip is dilated. Involvement of 
hepatocytes may not be uniform, so abnormalities may be found in some hepatocytes in 
some lobules and not in others. The mitochondrial changes are probably a consequence of 
oxidative damage from excessive liver copper.  
 
Clinical Presentation: 
The age at onset of symptoms generally ranges from 6 to about 40 years. WD with 
hepatic involvement has been identified in patients younger than 5 years and patients 
older than 60 years.  
Hepatic presentation 
Symptoms may be vague and nonspecific, such as fatigue, anorexia, and abdominal pain. 
Occasionally patients present with a self-limited clinical illness that resembles acute 
hepatitis, with malaise, anorexia, nausea, jaundice, elevated serum aminotransferases, and 
abnormal coagulation test results. Some patients have a history of self-limited jaundice, 
apparently caused by unexplained hemolysis.  
Patients may present with severe, established chronic liver disease—hepatosplenomegaly, 
ascites, congestive splenomegaly, a low serum albumin level, and persistently abnormal 
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coagulation test results. Some patients have isolated splenomegaly without 
hepatomegaly. Many of these findings relate more to portal hypertension as a 
consequence of WD than to the metabolic disorder itself. 
WD may manifest in children and young adults as clinical liver disease indistinguishable 
from autoimmune hepatitis 26. As in autoimmune hepatitis, the onset may be acute. 
Fatigue, malaise, arthropathy, and rashes may occur; laboratory findings include elevated 
serum aminotransferase levels, a greatly increased serum immunoglobulin (Ig) G 
concentration, and detectable nonspecific autoantibodies such as antinuclear and anti–
smooth muscle (anti-actin) antibodies. WD must be specifically ruled out because the 
treatment of the two diseases is entirely different. With appropriate treatment, the long-
term outlook for patients with WD that manifests as autoimmune hepatitis appears to be 
favorable, even if cirrhosis is present. 
WD may also manifest as fulminant hepatic failure, with severe coagulopathy and 
encephalopathy 27. Acute intravascular hemolysis is usually present, and renal failure 
may develop. Unlike fulminant viral hepatitis, fulminant WD is usually characterized by 
disproportionately low serum aminotransferase levels (usually much less than 1500 U/L) 
at the onset of clinically apparent disease. The serum alkaline phosphatase level is in the 
normal range or even low for age, and the serum bilirubin level is often 
disproportionately high as a result of hemolysis 28. A ratio of alkaline phosphatase 
concentration (IU/L) to bilirubin concentration (mg/dL) of less than two might be 
diagnostic of Wilsonian fulminant hepatitis 29,30. Slit-lamp examination of the eyes may 
demonstrate Kayser-Fleischer rings. Urinary copper excretion is greatly elevated. 
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Affected patients do not show a good response to chelation treatment and require urgent 
liver transplantation; albumin dialysis and related techniques may serve as temporary 
procedures until liver transplantation can be performed 31. 
Recurrent bouts of hemolysis may predispose to the development of gallstones.  Children 
with unexplained cholelithiasis, particularly with small bilirubinate stones, should be 
tested for WD. Unlike other types of chronic liver disease, WD is rarely complicated by 
hepatocellular carcinoma. 
In patients who have predominantly hepatic disease, evidence of subtle neurologic 
involvement often can be found. Mood disturbance (mainly depression, but sometimes 
impulsive or neurotic behavior), deterioration in school performance or handwriting, and 
clumsiness may be identified through careful questioning of the patient or his or her 
parents. A soft whispery voice (hypophonia) is another early feature of neurologic 
involvement. 
Neurological and neuropsychiatric presentation: 
Neurological and neuropsychiatric signs are the presenting features in 40–50% of patients 
with Wilson’s disease 32. The neurological abnormalities can be classified as: (a) an 
akinetic-rigid syndrome similar to Parkinson’s disease, (b) pseudosclerosis dominated by 
tremor, (c) ataxia, and (d) a dystonic syndrome 33. Subtle signs can appear before the 
characteristic neurological features, including changes in behaviour, deterioration of 
school work, or an inability to carry out activities that need good hand-eye coordination. 
Handwriting might deteriorate and micrographia—as in Parkinson’s disease—could 
develop. Other common neurological findings include tremor, lack of motor coordination, 
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drooling, dysarthria, dystonia, and spasticity. Along with behavioural changes, other 
psychiatric manifestations include depression, anxiety, and frank psychosis 7. 
 
Ocular signs 
The classic Kayser-Fleischer ring is caused by copper deposition in Descemet's 
membrane of the cornea 34. Copper is actually distributed throughout the cornea, but fluid 
streaming favors accumulation near the limbus, especially at the superior and inferior 
poles and, eventually, circumferentially around the iris. A careful slit-lamp examination 
is mandatory.  Sunflower cataracts can also be seen 35. Sunflower cataracts are brilliantly 
multicoloured and are visible only by slit-lamp examination. They do not impair vision. 
Both findings are reversible with medical therapy or after liver transplantation. Other less 
common findings include night blindness, exotropic strabismus, optic neuritis, and optic 
disc pallor.  
Kayser-Fleischer rings may be absent in 15% to 50% of patients with exclusively hepatic 
involvement and in presymptomatic patients, whereas most patients with a neurologic or 
psychiatric presentation of WD have Kayser-Fleischer rings; only 5% do not. Kayser-
Fleischer rings are not specific for WD. They may be found in patients with other types 
of chronic liver disease, usually with a prominent cholestatic component, such as primary 
biliary cirrhosis, primary sclerosing cholangitis, auto-immune hepatitis, and familial 
cholestatic syndromes. Kayser-Fleischer rings have also been reported in patients with 
nonhepatic diseases. 
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Involvement of the other organs 7 
WD can be accompanied by various extrahepatic disorders apart from neurologic disease. 
Episodes of hemolytic anemia can result from sudden release of copper into the blood. 
Renal disease, mainly Fanconi's syndrome, may be prominent. Findings include 
microscopic hematuria, aminoaciduria, phosphaturia, and defective acidification of the 
urine. Nephrolithiasis also has been reported. Arthritis, affecting mainly the large joints, 
may occur as a result of synovial copper accumulation. Other musculoskeletal problems 
are osteoporosis and osteochondritis dissecans. Vitamin D–resistant rickets may develop 
as a result of the renal damage. Copper deposition in the heart can lead to 
cardiomyopathy or cardiac arrhythmias. Sudden death in WD disease has been attributed 
to cardiac involvement but is rare. Copper deposition in skeletal muscle can cause 
rhabdomyolysis. Endocrine disorders can occur. Hypoparathyroidism has been attributed 
to copper deposition. Amenorrhea and testicular problems appear to result from WD 
itself, not from cirrhosis. Infertility or repeated spontaneous abortion may be a sign of 
WD. Pancreatitis, possibly resulting from copper deposition in the pancreas, may also 
occur. 
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Diagnosis of Wilson’s disease 
AASLD recommendations for diagnosis and screening for Wilson's disease 8 
 
Clinical features:  
WD should be considered in any individual between the ages of 3 and 55 years (Wilson's 
disease has been diagnosed in patients in their seventies) with liver abnormalities of 
uncertain cause. Age alone should not be the basis for eliminating a diagnosis of WD. 
 
WD must be excluded in any patient with unexplained liver disease along with 
neurological or neuropsychiatric disorder. 
 
In a patient in whom WD is suspected, Kayser-Fleischer rings should be sought by slit-
lamp examination by a skilled examiner. The absence of Kayser-Fleischer rings does not 
exclude the diagnosis of WD, even in patients with predominantly neurological disease. 
 
Diagnostic testing:  
An extremely low serum ceruloplasmin level (<50 mg/L or <5 mg/dL) should be taken as 
strong evidence for the diagnosis of WD. Modestly subnormal levels suggest further 
evaluation is necessary. Serum ceruloplasmin within the normal range does not exclude 
the diagnosis. 
 
Basal 24-hour urinary excretion of copper should be obtained in all patients in whom the 
diagnosis of WD is being considered. The amount of copper excreted in the 24-hour 
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period is typically >100 mcg (1.6 micromol) in symptomatic patients, but finding >40 
mcg (>0.6 micromol or >600 nmol) may indicate WD and requires further investigation. 
 
Penicillamine challenge studies may be performed for the purpose of obtaining further 
evidence for the diagnosis of WD in symptomatic children if basal urinary copper 
excretion is <100 mcg/24 hours (1.6 micromol/24 hours). Values for the penicillamine 
challenge test of >1600 mcg copper/24 hours (>25 micromol/24 hours) following the 
administration of 500 mg of D-penicillamine at the beginning and again 12 hours later 
during the 24-hour urine collection are found in patients with WD. The predictive value 
of this test in adults is unknown. 
 
Hepatic parenchymal copper content >250 mcg/g dry weight provides critical diagnostic 
information and should be obtained in cases where the diagnosis is not straightforward 
and in younger patients. In untreated patients, normal hepatic copper content (<40-50 
mcg/g dry weight) almost always excludes a diagnosis of WD. Further diagnostic testing 
is indicated for patients with intermediate copper concentrations (70-250 mcg/g dry 
weight) especially if there is active liver disease or other symptoms of WD. 
 
Neurologic evaluation and radiologic imaging of the brain, preferably by MR imaging, 
should be considered prior to treatment in all patients with neurologic WD and should be 
part of the evaluation of any patient presenting with neurological symptoms consistent 
with WD. 
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Mutation analysis by whole-gene sequencing is possible and should be performed on 
individuals in whom the diagnosis is difficult to establish by clinical and biochemical 
testing. Haplotype analysis or specific testing for known mutations can be used for family 
screening of first-degree relatives of patients with WD. A clinical geneticist may be 
required to interpret the results. 
 
Diagnostic considerations in specific target populations:  
Patients in the pediatric age bracket who present a clinical picture of autoimmune 
hepatitis should be investigated for WD. 
 
Adult patients with atypical autoimmune hepatitis or who respond poorly to standard 
corticosteroid therapy should also be investigated for WD. 
 
WD should be considered in the differential diagnosis of patients presenting with 
nonalcoholic fatty liver disease or have pathologic findings of nonalcoholic 
steatohepatitis. 
 
WD should be suspected in any patient presenting with acute hepatic failure with 
Coombs-negative intravascular hemolysis, modest elevations in serum aminotransferases, 
or low serum alkaline phosphatase and ratio of alkaline phosphatase to bilirubin of <2. 
First-degree relatives of any patient newly diagnosed with WD must be screened for WD. 
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Approach to diagnosis of Wilson disease (WD) in a patient with unexplained liver 
disease  
 
Molecular testing means confirming homozygosity for one mutation or defining two 
mutations constituting compound heterozygosity. 
CPN: ceruloplasmin; KF: Kayser-Fleischer. 
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Predictive value of diagnostic criteria of Wilson’s disease 
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Treatment of Wilson’s disease 
History of treatment of WD:  
In 1948, while investigating copper metabolism in demyelinating diseases, Mandelbrote 
et al.36  observed an increase in the urinary excretion of copper in patients injected with 
2,3 – dimercaptopropanol or BAL (British Anti – Lewisite). In 1951, Denny-Brown and 
Porter 37 and Cummings 38 introduced BAL as the first effective therapy for WD. 
Unfortunately the daily and indefinite intramuscular injection of BAL proved to be a 
painful and impractical form of therapy. Shortly thereafter J M Walshe (Cambridge, UK) 
introduced D-penicillamine (a dimethyl derivative of cysteine, which is found in the urine 
of patients on penicillamine) as an orally administered copper chelating agent. In 1956, 
Walshe introduced D-penicillamine into the pharmacopoeia and dramatically changed the 
profile of relentless progression of patients with untreated WD 2.  In 1969, Walshe 
introduced triethylene tetramine dihydrochloride or Trien as an alternative chelating 
agent to patients intolerant to D-penicillamine 39.  The use of zinc to decrease copper 
absorption may be attributed to Dick et al. who in 1954 reported that zinc 
supplementation in the diet of sheep led to a decrease in the liver copper content 40. It was 
Schouwink 6 in 1961 who reported the use of zinc for WD, but zinc use got approval by 
FDA only in 1997 41.  Recently a new drug ammonium tetrathiomolybdate has been used 
to treat neurological WD 42.  
 
D-Penicillamine: 
Penicillamine is cysteine, doubly substituted with methyl groups. A free sulphydryl group 
acts as the copper-chelator. D-penicillamine is rapidly absorbed from the gastrointestinal 
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tract with a double-peaked curve for intestinal absorption. Uptake may occur by an 
unusual mechanism: disulfide binding to the enterocyte membrane followed by 
pinocytosis. If D-penicillamine is taken with a meal, its absorption is decreased overall 
by about 50%. Total bioavailability is estimated at 40%-70%. Once absorbed, 80% of D-
penicillamine circulates bound to plasma proteins; there is little free D-penicillamine in 
the plasma, because it forms inactive dimers or binds to cysteine. Greater than 80% of D-
penicillamine excretion is via the kidneys. The excretion half-life of D-penicillamine is 
on the order of 1.7-7 hours, but there is considerable interindividual variation and D-
penicillamine or its metabolites can be found in the urine months after the drug has been 
discontinued. Total bioavailability after oral administration is 40–70%. More than 80% of 
penicillamine excretion is in urine, with chelated copper. Thus, penicillamine enhances 
urinary copper excretion but can also lead to the sequestration of free intracellular copper 
8. Penicillamine can also induce metallothionein, a cysteine-rich protein that is an 
endogenous chelator of metals.  
 
There are numerous studies that attest the efficacy of D-penicillamine as treatment of 
WD 43-49. Worsening of neurologic symptoms has been reported in 10%-50% of those 
treated with D-penicillamine during the initial phase of treatment 50,51,52. The hypothesis 
suggested for this phenomenon is that while penicillamine is mobilizing the very large 
store of hepatic copper, it temporarily further elevates the blood and brain levels of 
copper in the process 52.   
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D-Penicillamine use is associated with numerous side effects. Severe side effects 
requiring the drug to be discontinued occur in approximately 30% of patients 53. Early 
sensitivity reactions marked by fever and cutaneous eruptions, lymphadenopathy, 
neutropenia or thrombocytopenia, and proteinuria may occur during the first 1-3 weeks. 
D-Penicillamine should be discontinued immediately if early sensitivity occurs; the 
availability of alternative medications makes a trial of prednisone cotreatment 
unnecessary. Late reactions include nephrotoxicity, usually heralded by proteinuria or the 
appearance of other cellular elements in the urine, for which discontinuation of D-
penicillamine should be immediate. Other late reactions include a lupus-like syndrome 
marked by hematuria, proteinuria, positive antinuclear antibody and Goodpasture 
syndrome. Significant bone marrow toxicity includes severe thrombocytopenia or total 
aplasia. Dermatological toxicities reported include progeric changes in the skin and 
elastosis perforans serpingosa, and pemphigous or pemphigoid lesions, lichen planus, and 
aphthous stomatitis. Very late side effects include nephrotoxicity, severe allergic 
response upon restarting the drug after it has been discontinued, myasthenia gravis, 
polymyositis, loss of taste, immunoglobulin A depression, and serous retinitis. 
Hepatotoxicity has been reported. Hepatic siderosis has been reported in treated patients 
with reduced levels of serum ceruloplasmin and non–ceruloplasmin bound copper 8.  
 
Tolerability of D-penicillamine may be enhanced by starting with incremental doses, 
250-500 mg/day, increased by 250 mg increments every 4-7 days to a maximum of 1000-
1500 mg/day in 2-4 divided dosages. Maintenance dose is usually 750-1000 mg/day 
administered in two divided doses. Dosing in the child is 20 mg/kg/day given in two or 
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three divided doses. D-Penicillamine is best administered 1 hour prior to or 2 hours after 
meals, because food inhibits its absorption. Serum ceruloplasmin may decrease after 
initiation of treatment. Serum ceruloplasmin may then either remain low or increase over 
the term of chronic treatment, the latter occurring in some patients with severe hepatic 
insufficiency as they recover synthetic function in response to treatment. In contrast, 
decrease in serum ceruloplasmin levels in patients treated chronically with penicillamine 
may be a sign of excessive copper depletion and often is associated with neutropenia, 
sideroblastic anemia, and hemosiderosis. 
 
Adequacy of treatment is monitored by measuring 24-hour urinary copper excretion 
while on treatment. This is highest immediately after starting treatment and may exceed 
1000 µg (16 µmol) per day at that time. With chronic (maintenance) treatment, urinary 
copper excretion should run in the vicinity of 200-500 µg (3-8 µmol) per day on 
treatment. In addition, estimate of non–ceruloplasmin bound copper shows normalization 
of the non–ceruloplasmin bound copper concentration with effective treatment. Values of 
urine copper excretion below 200 µg/day (3.2 µmol/day) may indicate either 
nonadherence to therapy or overtreatment and excess copper removal. In those with 
nonadherence to therapy, non–ceruloplasmin bound copper is elevated (>15 µg /dL or 
>150 µg /L) while with over treatment, values are very low (<5 µg /dL or <50 µg /L) 8. 
 
Trientine:  
Trientine (triethylene tetramine dihydrochloride or 2,2,2-tetramine, also known by its 
official short name trien) is one of a family of chelators with a polyamine-like structure 
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chemically distinct from penicillamine. It lacks sulfhydryl groups and copper is chelated 
by forming a stable complex with the four constituent nitrogens in a planar ring. Trientine 
was introduced in 1969 as an alternative to penicillamine. It is poorly absorbed fromthe 
gastrointestinal tract.  
 
The amounts of urinary copper, zinc and iron increase in parallel with the amount of 
trientine excreted in the urine 54. Like penicillamine, trientine promotes copper excretion 
by the kidneys. Trientine is effective treatment for WD and is indicated especially in 
patients who are intolerant of penicillamine or have clinical features indicating potential 
intolerance (history of renal disease of any sort, congestive splenomegaly causing severe 
thrombocytopenia, autoimmune tendency) 55. Neurological worsening after beginning 
treatment with trientine has been reported but appears much less common than with 
penicillamine. Trientine has also been shown to be effective initial therapy for patients, 
even with decompensated liver disease at the outset 56. Trientine has few side effects. No 
hypersensitivity reactions have been reported although a fixed cutaneous drug reaction 
was observed in one patient. Pancytopenia has rarely been reported. Trientine also 
chelates iron, and coadministration of trientine and iron should be avoided because the 
complex with iron is toxic. A reversible sideroblastic anemia may be a consequence of 
overtreatment and resultant copper deficiency. Lupus-like reactions have also been 
reported in some WD patients treated with trientine.   
 
Typical dosages are 750-1500 mg/day in two or three divided doses, with 750 or 1000 mg 
used for maintenance therapy. In children, the weight-based dose is not established, but 
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the dose generally used is 20 mg/kg/day rounded off to the nearest 250 mg, given in two 
or three divided doses. Trientine should be administered 1 hour before or 2 hours after 
meals. Adequacy of treatment is monitored by measuring 24-hour urinary copper 
excretion while on treatment. This should run in the vicinity of 200-500 µg (3-8 µmoles) 
per 
day on maintenance treatment but may be higher when treatment is first started. 
Additionally, estimate of non–ceruloplasmin bound copper may show normalization of 
the non–ceruloplasmin bound copper concentration with effective treatment. Values of 
urine copper excretion below 200 µg/day 
(3.2 µmol/day) may indicate either nonadherence to therapy or overtreatment and excess 
copper removal. In those with nonadherence to therapy, non–ceruloplasmin bound copper 
is elevated (>15 µg/dL or >150 µg/L), whereas with overtreatment, values are very low 
(<5 µg/dL or <50 µg/L) 8. 
 
Zinc: 
The mechanism of action of zinc is different from that of penicillamine and trientine. 
Zinc intereferes with the uptake of copper from the gastrointestinal tract. Oral ingestion 
of zinc induces in intestinal cells the synthesis of a protein, metallothionein, a cysteine-
rich protein that is an endogenous chelator of metals 7,57. Metallothionein has greater 
affinity for copper than for zinc and thus preferentially binds copper present in the 
enterocyte and inhibits its entry into the portal circulation. Once bound, the copper is not 
absorbed but is lost into the fecal contents as enterocytes are shed in normal turnover. 
Because copper also enters the gastrointestinal tract from saliva and gastric secretions, 
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zinc treatment can generate a negative balance for copper and thereby remove stored 
copper 58. Zinc may also act by inducing levels of hepatocellular metallothionein 59.  
 
Zinc has very few side effects. Gastric irritation seen in 5 to 10% of patients and may be 
dependent on the salt employed 41. Zinc sulfate has more gastric irritant effects than zinc 
acetate. This can be easily ameliorated by taking the first dose of the day mid-morning, 
rather than before breakfast 42.  Other findings noted with zinc therapy include possible 
immunosuppressant effects and reduced leucocyte chemotaxis but one study found no 
adverse effect on lymphocyte function with chronic use 60. Elevations of amylase and 
lipase that tend to occur during the first year of zinc therapy are attributed to inductions 
of these enzymes by zinc and therefore a greater release in the plasma 60. Studies have 
noted that zinc  has  an effect on  reducing high density  lipoprotein cholesterol,  the  type  
of  cholesterol  associated  with  reducing  the  risk  of coronary  heart  disease 61,62. 
Brewer et al.; have studied cholesterol metabolism in zinc treated patients with Wilson's 
disease and  found no harmful effects 41,63.  
 
Brewer et al.; have recommended elemental zinc dosages as follows: 25 mg x 2 until age 
6, 25 mg x 3 until age 16 or until reaching a weight of 125 pounds, and then the regular 
dose of 50 mg x 3 41. This study also states that the above doses provide a margin of 
safety.  If a patient forgets his or her medication over a  few days such as a weekend,  the 
metallothionein  in  the  intestinal  tract will stay  induced  (the  half-life  of deinduction  
is  11  days) and the patient will continue to be protected 41.  Adequacy of treatment with 
zinc is judged by clinical and biochemical improvement and by measuring 24-hour 
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urinary excretion of copper, which should be less than 75µg (1.2 µmol) per 24 hours on 
stable treatment. Additionally, estimate of non–ceruloplasmin bound copper shows 
normalization of the non–ceruloplasmin bound copper concentration with effective 
treatment. Urinary excretion of zinc may be measured from time to time to check 
compliance 8. Patients on zinc also have a risk of being over treated. This would be 
manifest with a urine copper level that drops below 35 µg/24 hours (normal 20 to 50 µg) 
and later by hypochromic microcytic anemia and leucopenia. It is suggested to lower the 
dose of zinc 41.  
 
Ammonium Tetrathiomolybdate (TM):  
TM is a very strong decoppering agent which works by two mechanisms: interfering with 
intestinal uptake of copper (if administered with meals) and binding copper from plasma 
(when taken between meals). At low doses, TM removes copper from metallothionein, 
but at higher doses it forms an insoluble copper complex, which is deposited in the liver 
8,42. TM has been used in Wilson’s disease for the initial treatment of the neurologically 
presenting patient and is currently being investigated for the initial treatment of the 
hepatic presentation as well. The dose is 120 mg/day, 20 mg three times/day with meals, 
and 60 mg at bedtime away from food, given for eight weeks, concomitant with zinc 
therapy. The measure of efficacy has been the rate of neurological deterioration, which 
has been less than 5% with TM (compared to 50% for penicillamine and a little less than 
20% for trientine) 64.  
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TM has a good safely profile. There is a 10–15% incidence of overtreatment 
anemia/leukopenia, responsive to lowering the dose. There is also a 10–15% incidence of 
a mild further increase in transaminase enzymes, probably due to TM’s ability to shift 
copper out of hepatic metallothionein pools. This, too, is quickly responsive to lowering 
the dose. Currently a study is underway to see if a lower dose given longer will preserve 
efficacy and reduce side effects 64.  
 
 
Role of Diet in treatment of Wilson’s disease 8:  
Foods with very high concentrations of copper (shellfish, nuts, chocolate, mushrooms, 
and organ meats) generally should be avoided, at least in the first year of treatment. Diets 
deficient in copper may delay the onset of the disease and control disease progression, but 
dietary management is not recommended as sole therapy. Well water or water brought 
into the house hold through copper pipes should be checked for copper content, but in 
general, municipal water supplies do not have to be checked. A water purifying system 
may be advisable if the copper content of the water is high. For those with copper pipes, 
it is important to flush the system of stagnant water before using water for cooking or 
consumption. Copper containers or cookware should not be used to store or prepare foods 
or drinks. 
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Treatment of Wilson’s disease in Specific Clinical Situations 
 
Asymptomatic patients: 
Presymptomatic patients are those that are diagnosed before becoming clinically ill. 
Usually these will be siblings of an affected patient who are diagnosed as a result of 
family screening. Occasionally a presymptomatic patient will be dentified when routine 
ophthalmologic examination reveals Kayser-Fleischer rings, or when routine serum 
biochemistries reveal elevated serum transaminase enzymes. These patients may be 
viewed as equivalent to symptomatic patients who have received initial therapy and are in 
the maintenance phase of treatment. They can be treated either with chelating agent D-
penicillamine/ trientine monotherapy or with zinc monotherapy 3,42,65,66,67,68.  
 
Initial therapy – neurologic patients: 
A major problem exists with the initial therapy of neurologic patients in that all of the 
drugs currently available commercially have defects in treating these patients. 
Penicillamine has a high rate (10 - 50%) of causing neurologic worsening, probably by 
mobilizing hepatic copper and temporarily further elevating brain copper 50,51,52. About 
half of the patients who worsen never recover to their prepenicillamine baseline. 
Trientine, which is a chelator like penicillamine, appears to have about a 20% risk of 
causing neurologic worsening 69. It is suggested to start at a lower dose of chelator and 
gradually hike to the optimal dose to prevent neurological worsening. Linn et al.; have 
reported a good clinical outcome of patients with neurologic WD treated with exclusive 
zinc therapy with a median follow up of 14 years 70.  
 35
 
Initial therapy – Hepatic patients: 
If the patient simply has transaminase elevations, or cirrhosis and transaminase 
elevations, but no evidence of hepatic decompensation in terms of low albumin, elevated 
bilirubin, and prolonged prothrombin time, the patient may be treated as a maintenance 
phase patient with zinc or trientine  42.  
 
Patients who present with decompensated chronic liver disease, typically with 
hypoalbuminemia, prominent coagulopathy, ascites, but no encephalopathy, have 
recently been treated with a chelator, either D-penicillamine or trientine plus zinc 8. There 
are at present no recommendations to start zinc therapy in symptomatic and 
decompensated liver disease patients. The study by Linn et al.; in which exclusive zinc 
therapy for WD patients, concluded a less favourable outcome for patients with hepatic 
presentation. Two of the twelve patients with compensated cirrhosis deteriorated on 
follow up needing for liver transplantation 70.  
 
Patients with acute liver failure due to WD require liver transplantation which is life 
saving 71. To help determine which patients with acute hepatic presentations will not 
survive without liver transplantation, Nazer et al.; developed a prognostic score whose 
components include serum bilirubin, serum aspartate aminotransferse, and prolongation 
of prothrombin time 72. The study implies that patients with scores of 6 or below were 
likely to survive on penicillamine therapy, while those with scores of 7 or above were not 
unless transplanted 72.  
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Nazer score 72 
 
 
Maintenance therapy: 
As per the AASLD practice guidelines, after adequate treatment with a chelator, stable 
patients may be continued on a lower dosage of the chelating agent or shifted to treatment 
with zinc 8. The advantages of long-term treatment with zinc include that it is more 
selective for removing copper than penicillamine or trientine and is associated with few 
side effects. The study by Brewer et al on 141 patients, it was concluded that zinc is 
effective as the sole therapy in long term treatment maintenance treatment of Wilson’s 
disease 73. The prospective study of Czlonkowska et al.; compared the clinical outcome in 
patients treated with penicillamine or zinc. They concluded that both drugs were equally 
effective in the long term of treatment of WD. The tolerance profile was in favour of zinc 
sulfate 49.  
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Pregnancy:  
In pregnant women, treatment must be maintained throughout the course of pregnancy 
for all patients with WD. Experience to date indicates the chelating agents (both 
penicillamine and trientine) and zinc salts  have been associated with satisfactory 
outcomes for the mother and fetus 74,75,76,77. Birth defects are rare. The dosage of zinc 
salts is maintained throughout without change; however, dosages of chelating agents 
should be reduced to the minimum necessary during pregnancy, especially for the last 
trimester to promote better wound healing if cesarean section is performed. Such a dose 
reduction might be on the order of 25%-50% of the pre pregnancy dose. Patients should 
be monitored frequently during pregnancy. Women taking D-penicillamine should not 
breast-feed because the drug is excreted into breast milk and might harm the infant. Little 
is known about the safety of trine tine and zinc in breast milk 8. 
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Aim 
 
• To study the efficacy of initial chelation with penicillamine followed by zinc 
monotherapy in symptomatic Wilson’s disease. 
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Material and Methods 
We performed an open retrospective and prospective observational cohort study to 
evaluate the efficacy, safety and outcomes of symptomatic WD patients treated with 
initial penicillamine followed by zinc monotherapy. The study was approved by the 
Institutional Review Board and Ethics Committee. Written consent was taken from all 
patients included in the study. The study was conducted over a period of 2 years from 
October 2007 to October 2009 in the Department of Gastrointestinal Sciences at CMC, 
Vellore. 
 
Inclusion Criteria: 
• Symptomatic WD (Hepatic +/- Neuropsychiatric) on treatment with penicillamine 
 Hepatic manifestations included jaundice, ascites, gastrointestinal bleed, encephalopathy, 
abdominal pain or spontaneous bacterial peritonitis. 
 
Exclusion criteria: 
• Diagnosis other than WD / doubtful WD  
• Atypical copper deposition disease 
•  Presymptomatic  WD  
• Any  other coexisting liver disease 
• WD treated with any other regime 
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Sample Size: 
This was an observational cohort study. We estimated that during the study duration 
about 20 patients would be on follow up with the aforementioned treatment regime in our 
unit. 
 
Methodology: 
The database of patients with the diagnosis of WD was generated using medical records 
and a prior genetic base study. Pharmacy records of these patients were retrieved online. 
The patients who were initially on D-penicillamine and changed to zinc sulphate later on 
were screened and all those who fulfilled all the inclusion criteria and had none of the 
exclusion criteria were recruited and formed the study cohort.  
 
The diagnosis of Wilson’s disease was made based on clinical presentation of liver 
disease and confirmatory tests which included serum Ceruloplasmin values, 24 hours 
urinary copper excretion with or without presence of Kay Fleischer ring.  Percutaneous or 
transjugular liver biopsy for assessing the histology and dry weight of copper and ATB 
7B gene mutation analysis were done as and when clinically indicated.   
 
Those patients who were on penicillamine at the start of the study changed over to zinc 
because of financial constraints or adverse effects. The change over from penicillamine to 
zinc was gradual, by tapering and stopping penicillamine over a few months in those 
patients who attained clinical stability with initial chelation with penicillamine but had 
financial constraints. In contrast in those patients who had adverse effects to 
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penicillamine, the drug was abruptly stopped and changed to zinc. The dose of 
penicillamine used in the study cohort varied from 250 mg bid to 250 mg qid. The dose 
of zinc sulphate varied from 140 mg bid to 140 mg tid. The study cohort was followed up 
periodically on outpatient basis and as inpatients during hospital admissions. The patients 
were seen by the primary investigator on each follow up visit and clinical worsening or 
improvement was recorded. In addition at each of these visits, compliance and adverse 
effects to zinc sulphate were noted. Compliance was assessed by enquiring the patient or 
their parents about regular drug intake. The patients had periodic monitoring of 
hemoglobin, total and differential white cell counts, platelet count, liver function tests 
and prothrombin time, although all tests were not ordered at each visit by the treating 
physician. Urinary copper and ceruloplasmin values on follow up were also noted, if 
available.  
 
The results were analyzed based on the clinical and laboratory parameters from entry into 
study and till October 2009. The data entry and analysis was done using Microsoft Excel 
and Graphpad Instat 3. ANOVA was the statistical test used for comparing the means of 
variables at baseline, on penicillamine and on zinc therapy. 
 
The laboratory parameters (hemoglobin, total and differential white cell counts, platelet 
count, liver function tests, prothrombin time, 24 hour urinary copper excretion) at 
presentation, on penicillamine and on zinc therapy were compared. We calculated the 
Model for End Stage Liver Disease (MELD), Nazer score and New Wilson Index for 
predicting Mortality at presentation, on penicillamine and on zinc subject to availability 
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of laboratory parameters at each visit. The outcome parameters studied were morbidity 
and mortality, complications of liver disease and changes in laboratory parameters on 
treatment with each drug. The side effect profile was also studied. 
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Results 
Demographic profile: 
202 patients were screened out of which 28 who fulfilled all the inclusion criteria and had 
none of the exclusion criteria were recruited into the study. The study included 28 
patients, males (n=18) and females (n=10). The mean age of subjects was 17.5 ± 6.19 
years.  
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                      Figure 1 – Figure to show the sex distrubution of patients 
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Twenty four patients had pure hepatic manifestations. Hepatic and neurological 
symptoms were present in two patients. 2 others had psychiatric complaints in addition.  
 
Twenty four patients presented with some form of hepatic decompensation, whereas the 
remaining had abdominal pain as the chief complaint. The patients had the following 
hepatic symptoms: ascites (n=16), jaundice (n=14), abdominal pain (n=8), 
gastrointestinal bleeding (n=4) and encephalopathy (n=2).  
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            Figure 2 – Figure to show the distribution of hepatic manifestations 
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The neurological presenting features were drooling of saliva (n=2), writing difficulty 
(n=1), rigidity (n=1) and abnormal movements (n=1). Psychiatric manifestations included 
poor scholastic performance and cognitive decline (n=1) and behavioral changes (n=1). 
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           Figure 3 - Figure to show the distribution of neurological manifestations 
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Psychiatric manifestations included poor scholastic performance and cognitive decline 
(n=1) and behavioral changes (n=1). 
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       Figure 4 - Figure to show the distribution of psychiatric manifestations 
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Duration of treatment: 
The mean duration of penicillamine therapy was 123.92 weeks (SD: 94.18; range: 2-320 
weeks). The mean duration of zinc therapy was 175.92 weeks (SD: 122.82; range: 21 to 
352 weeks). The mean duration of therapy was significantly longer for zinc compared to 
penicillamine (p=0.03).  
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             Figure 5 - Figure to show mean duration of penicillamine and zinc therapy 
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Figure 6 - Figure to show duration of penicillamine and zinc therapy in individual 
subjects 
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Statistical analysis and results: 
The Analysis of Variance (ANOVA) test was used to look for variation among means of 
variables at baseline, on penicillamine and zinc monotherapy. 
 
The mean serum bilirubin values at presentation, on penicillamine and on zinc were 3.88 
mg%, 1.73 mg% and 1.56 mg% respectively. The variation among the aforementioned 
mean values of bilirubin was not significant (p=0.0778). So also, no statistically 
significant difference was obtained when the following means of serum bilirubin were 
compared a) at presentation vs penicillamine (p >0.05)  b) at presentation vs zinc 
monotherapy (p >0.05)  c) penicillamine vs zinc monotherapy  (p>0.05).  
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            Figure 7 - Figure to show the mean bilirubin values on sequential follow up 
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The mean serum albumin values at presentation, on penicillamine and on zinc were 2.73 
mg%, 3.49 mg% and 3.95 mg% respectively. The variation among the means between 
the various groups was highly significant on ANOVA testing (p= 0.0001). There was 
statistically significant difference on comparing the mean serum albumin at presentation 
with both penicillamine treatment (p<0.01) and zinc monothearpy (p<0.01). However, no 
significant difference was found when penicillamine and zinc were compared (p>0.05). 
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             Figure 8 - Figure to show the mean albumin values on sequential follow up 
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The mean hemoglobin values at presentation, on penicillamine and on zinc were 10.26 
gm%, 11.49 gm% and 11.83 gm% respectively. There was no statistically significant 
differences in the mean hemoglobin values on penicillamine and on zinc (p>0.05). There 
was statistically significant difference on comparing mean hemoglobin values at 
presentation versus penicillamine (p<0.05) and zinc (p<0.05).  
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             Figure 9 – Figure to show the mean hemoglobin values on follow up 
 
 
 52
 
 
The mean total count at presentation, on penicillamine and on zinc were 7144 cells/cmm, 
5339 cells/cmm and 4913 cells/cmm respectively. There was significant difference 
between mean total counts at presentation versus zinc (p<0.05). In contrast, there was no 
statistically significant difference between the mean total count at presentation vs that on 
penicillamine treatment (p>0.05) and on penicillamine vs zinc (p>0.05).  
 
The mean platelet count at presentation, on penicillamine and on zinc were 1,29,290 
cells/cmm, 1,10,955 cells/cmm and 1,07,683 cells/cmm. There was no statistically 
significant difference in the mean platelet count at presentation, on penicillamine and on 
zinc (p>0.05). 
 
The mean prothrombin time at presentation, on penicillamine and on zinc were 20.8 
seconds, 15.9 seconds and 14.6 seconds respectively. The variation among the means 
between the various groups was highly significant (p= 0.0004). There were statistically 
significant differences when the prothrombin time at presentation was compared with that 
on penicillamine (p<0.01) and zinc (p<0.001). This was not the case when the mean 
prothrombin time on penicillamine and on zinc were compared (p<0.05).  
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             Figure 10 - Figure to show the mean prothombin time values on follow up  
 
 
The mean 24 hour urinary copper values at presentation, on penicillamine and on zinc 
were 578.61 µg, 631.46 µg and 195.35 µg respectively. The variation among the means 
between the various groups was highly significant (p= 0.0004). There was a significant 
difference in the mean 24 hour urinary copper values on penicillamine vs zinc (p<0.01) 
as well as at presentation vs on zinc (p<0.01). However, values at presentation vs on 
penicillamine did not yield significant results (p>0.05).  
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              Figure 11 – Figure to show the mean 24 hour urinary copper on follow up 
 
 
The mean Model for End Stage Liver Disease (MELD) scores at presentation, on 
penicillamine and on zinc were 11.71, 4.5 and 5.4 respectively. The variation among the 
means between the various groups was highly significant (p= 0.0002). There was a 
statistically significant difference in the MELD score at presentation vs both on 
penicillamine and on zinc (p<0.001 and p<0.01 respectively). This significant difference 
was not observed when the MELD scores on penicillamine and zinc were compared 
(p>0.05).  
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The mean Nazer scores at presentation, on penicillamine and on zinc were 3.09, 0.57 and 
0.59 respectively. The variation among the means between the various groups was highly 
significant on ANOVA testing (p= 0.0001). There was a statistically significant 
difference in the Nazer score at presentation vs both penicillamine (p<0.01) and zinc 
(p<0.01). The mean Nazer score showed no significant difference on penicillamine vs 
zinc (p>0.05).  
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             Figure 12 – Figure to show the mean Nazer score on sequential follow up 
 
 
The mean New Wilson Index for Predicting Mortality at presentation, on penicillamine 
and on zinc was 6.31, 2.26 and 2.19 respectively. The variation among the means 
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between the various groups was highly significant (p= 0.0001). There was statistically 
significant differences in the mean index when baseline values were compared with 
penicillamine (p<0.001) as well as zinc (p<0.001). When the comparison was made 
between penicillamine and zinc the difference was not statistically significant (p>0.05).  
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Figure 13 – Figure to show the trend of various biochemical and hematological 
parameters and clinical scores at baseline and on therapy 
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 Mean Values P value 
Variable Baseline Penicillamine Zinc Baseline vs 
Penicillamine
Baseline 
vs Zinc 
Penicillamine 
vs Zinc 
Bilirubin 3.88 1.73 1.51 >0.05 >0.05 >0.05 
Albumin 2.73 3.49 3.95 <0.01 <0.01 >0.05 
PT 20.8 15.9 14.6 <0.01 <0.001 >0.05 
MELD 11.71 4.5 5.4 <0.001 <0.01 >0.05 
Nazer 
score 
3.07 0.57 0.59 <0.01 <0.01 >0.05 
NWI 6.31 2.26 2.19 <0.001 <0.001 >0.05 
 
Table 1 - Table to show the mean values of the variables and comparison of p values 
amongst different groups 
 
The dose of penicillamine varied from 250 mg twice a day to 250 mg four times per day. 
Patients were given 20 mg of pyridoxine along with penicillamine. The dose of zinc 
sulfate varied from 140 mg twice a day to 140 mg thrice a day. 
 
3 patients were lost to follow up after starting zinc monotherapy. All patients except one 
who had recently begun treatment with zinc had at least one visit post initiation of zinc 
treatment.  
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Adverse effects and Complications on treatment: 
Patients on penicillamine had severe life threatening side effects which included 
neutropenia (n=3), thrombocytopenia (n=1), anemia (n=1) and proteinuria (n=1). In stark 
contrast, adverse effects noted with zinc were minimal. Only one patient complained of 
dyspepsia while on zinc therapy which subsided with empirical treatment. 
 
Complications noted with penicillamine therapy were more severe as well as more 
common than those with zinc. The frequent complications noted in patients on 
penicillamine were spontaneous bacterial peritonitis (n=4) {after 2 weeks, 4 weeks, 1 
month and 3 months of penicillamine respectively}; variceal bleed (n=3) {2 months, 9 
months and 2 years of penicillamine respectively}; and portal colopathy related rectal 
bleeding (n=1) {2 months of penicillamine}. Other features noted were speech 
disturbances and poor scholastic performance in one patient and serositis causing pleural 
effusion in another.  
 
Three patients had variceal bleed while on zinc. They developed variceal bleed after 9 
months, 17 months and 20 months respectively of treatment with zinc. Two of these 
patients had had an earlier variceal bleed while on penicillamine. There were no other 
complications of liver disease while on zinc. Drooling of saliva and behavioral changes 
were noted in one patient 5 years after being initiated on zinc treatment.  
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Follow up: 
There was one death on follow up. This patient, who had presented with hepatic 
decompensation continued to be in a decompensated state while on treatment and later 
succumbed to septic complications. This happened 57 weeks of zinc treatment which was 
initiated after 14 weeks of penicillamine. 
 
The compliance with zinc was 100%. One patient stopped penicillamine for 2 weeks, 
reasons for which are not known.  
 
Out of the 28 patients, 24 were decompensated at presentation. Three patients, who had 
initially presented with decompensation, were lost to follow up after being initiated on 
zinc. 18 patients became compensated while on zinc after an initial period of 
penicillamine. 
 
Two patients had a Nazer score ≥ 7 at baseline which is an indicator of higher chances of 
mortality without liver transplantation. Both these patients were managed successfully 
with penicillamine followed by zinc. Both these patients are still surviving on zinc 
monotherapy.  
 
 
 
 
 
 60
Discussion 
Ours is a partly retrospective and partly prospective observational cohort study. This 
research project primarily studied symptomatic patients of WD with hepatic (+/- 
neurological/psychiatric) manifestations. The patients were initiated on decoppering 
therapy with penicillamine but were unable to continue it due to financial constraints or 
development of adverse effects. The patients were subsequently initiated on zinc 
monotherapy.  
 
This is the largest series of patients with symptomatic hepatic Wilson’s disease. There is 
an adequate duration of follow up after initiating patients on zinc with a mean follow up 
of 3 years 4 months. Earlier studies with zinc monotherapy having large sample size 
include patients in presymptomatic stage 67 or with neurological WD 49,78.  
 
The American Association for the Study of Liver Diseases does not at present 
recommend the use of zinc in patients with symptomatic hepatic WD 8. Zinc has been 
used from the start as monotherapy in the series by Linn et al. 70 and Hoogenraad et al. 79, 
which included symptomatic neurological and hepatic WD patients. The study by Brewer 
et al. 41 uses zinc as the sole maintenance therapy after patients were initially treated with 
chelating agents. Earlier studies include case reports of patients who were treated with 
zinc only when patients had adverse effects to penicillamine or there was deterioration of 
neurological symptoms 52. There are few case reports of the successful use of zinc 
monotherapy in patients presenting primarily with hepatic symptoms 80,81,82.  
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Our study shows a favourable trend of hematological (hemoglobin, prothrombin time) 
and biochemical parameters (serum albumin) on penicillamine as compared to baseline 
which was statistically significant. This positive trend in the parameters persists after 
switching over to zinc therapy.  
 
There was no statistical difference in the means of biochemical parameters between 
penicillamine and zinc monotherapy. Serum bilirubin values also improve on therapy but 
the trend was not statistically significant.  
 
The improvement in the MELD score 83, Nazer score 72 and New Wilson disease index 
for predicting mortality 84 between baseline and penicillamine therapy persists on zinc 
therapy which is of marked clinical significance.  
 
The 24 hour urinary copper values shows a significant rise on penicillamine therapy 
which is not seen on zinc therapy (p<0.01) which reiterates the fact that zinc primarily 
acts by preventing copper absorption from the gastrointestinal tract where as 
penicillamine acts by chelation of body copper stores and hence the high levels of copper 
in urine on penicillamine therapy.  
 
Four decompensated patients received penicillamine for less than six months (2, 8, 12 
and 14 weeks respectively). 3/24 decompensated patients were lost to follow up. One 
decompensated patient who was changed over to zinc at 14 weeks of penicillamine 
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monotherapy due to anemia remained decompensated on zinc therapy and died due to 
gram negative sepsis after 57 weeks of zinc therapy.  
 
The side effect profile was similar as documented earlier in literature 7,8.  Patients on 
penicillamine had severe life threatening haematological side effects which included 
neutropenia, thrombocytopenia, anemia as well as proteinuria. In stark contrast, adverse 
effects noted with zinc were minimal and amenable to therapy. 
 
Overall compliance was good with both the drugs except for one patient stopping 
penicillamine therapy for 2 weeks, details of which were not available. No patient 
stopped zinc.  
 
The study by Linn et al 70 used zinc monotherapy from the diagnosis for symptomatic 
neurological and hepatic WD. Although the outcome for neurological WD was good, a 
few (2/12) patients with hepatic WD deteriorated on therapy with an unfavorable 
outcome. In contrast the study by Sinha et al. 78 that studied patients of neurological WD, 
there was a mean duration of initial combination therapy with penicillamine and zinc for 
107.4 months before shifting over to zinc monotherapy. The patients in the study groups 
showed a statistically significant improvement in their neurological scores on zinc 
therapy after initial combination therapy. In our study, 24/28  subjects had a minimum 
period of six months  of  decoppering with penicillamine before switching over to zinc (4 
patients were changed over to zinc earlier due to severe adverse effects to penicillamine).  
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The very fact that all decompensated patients who received adequate initial chelation 
with penicillamine became compensated continue to be so on zinc monotherapy with 
negligible side effects implies that zinc is an ideal agent for maintenance therapy after 
initial chelation in hepatic WD. 
 
The major limitation of our study was that it was partly retrospective.  
 
At present there is no prospective data to find out the exact duration of penicillamine 
chelation therapy required to stabilize a patient. A prospective trial with varying 
durations of initial chelation therapy with penicillamine followed by zinc monotherapy 
will be of utmost importance. However the duration of penicillamine therapy shall always 
be guided by the clinical and laboratory parameters in an individual patient. A 
prospective head to head trial between patients on exclusive penicillamine and those on 
penicilliamine/zinc sequential therapy would be beneficial.  
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Conclusions 
 
1. Penicillamine is a good drug for initial chelation therapy for patients with 
symptomatic Wilson’s disease. 
 
2. Penicillamine has serious and life threatening adverse effects. 
 
3. Zinc can be used as a monotherapy for symptomatic patients of WD, provided 
patients are adequately chelated and stabilized on penicillamine initially. 
 
4. Zinc has minimal and tolerable non life threatening adverse effects. 
 
5. Initial chelation with penicillamine followed by maintenance zinc 
monotherapy is an efficacious regime to treat symptomatic patients of hepatic 
Wilson’s disease. 
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Proforma 
Patient Study Number: Date of 1st presentation to CMC: 
Name:              Date of Birth:  
Age:                                        Sex:   Consanguineous Marriage: Y / N  
Fathers Name:             Name of Mother : 
Siblings 
Name Date of Birth / Age Affected 
   
   
   
   
 
Postal Address:    
 
Phone No: a) b)                                          
Email: 
Diagnostic Criteria for Wilsons Disease: 
 
Mode of Presentation:    
Mode Features Age of onset 
of 
symptoms 
Details  
H
ep
at
ic
 
  
Symptomatic   
Asymptomatic   
N
eu
ro
lo
gi
ca
l 
  
Symptomatic   
Asymptomatic   
Psychiatric 
 
   
Others  
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Kay-Fleischer Ring:     Present / Absent 
 
Penicillamine therapy profile     
 
Date of Onset:   
Date stopped:                                      
Duration taken: 
 
 
 
Date        
Hb        
TC        
DC        
Platelet        
PT        
INR        
T. Prot        
Albumin        
T. Bili        
D. Bili        
AST        
ALT        
ALP        
Creatinine        
Serum 
Ceruloplasmin 
       
24 hr urinary  
copper 
       
 
 
 
Date Weight Dose Compliance 
(Y/N) 
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Complications of Liver Disease on Penicillamine therapy 
 Dates Details Duration of Penicillamine 
therapy 
Variceal bleed  
 
  
Ascites  
 
  
Hepatic enceph  
 
  
Any other  
 
  
 
Details of  worsening of disease on treatment:  
 
Exact duration of treatment stopped when on penicillamine and reason: 
 
 
Side effects attributable to Penicillamine treatment 
Side effects Dates Details Duration of Penicillamine 
therapy 
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Zinc therapy profile:                            Zinc sulphate / Zinc acetate 
 
Date of Onset:   
Date stopped:                                      
Duration taken: 
 
 
 
 
Date        
Hb        
TC        
DC        
Platelet        
PT        
INR        
T. Prot        
Albumin        
T. Bili        
D. Bili        
AST        
ALT        
ALP        
Creatinine        
Serum 
Ceruloplasmin 
       
24 hr urinary  
copper 
       
 
 
 
 
Date Weight Dose Compliance 
(Y/N) 
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Complications of Liver Disease during Zinc Monotherapy 
 Dates Details Duration of Zinc therapy 
Variceal bleed  
 
  
Ascites  
 
  
Hepatic enceph  
 
  
Any other  
 
  
 
Details of worsening of disease on treatment:  
 
Exact duration of treatment stopped when on zinc and reason: 
 
 
 
Side effects attributable to Zinc treatment 
Side effects Dates Details Duration of Zinc therapy 
  
 
  
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
  
 
 
Exact details how Penicillamine changed to zinc: 
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  At presentation On stopping 
penicillamine 
On zinc 
monotherapy 
Nazer Score     
New WD PI    
CPT score    
MELD score    
 
USG Abdomen     Date: 
Report: 
      
OGD       Date: 
Report: 
 
Follow Up Remarks: 
Date Remarks/Quality of life  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Iron indices on treatment: 
 
 
Death if any details:  
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OBJECTIVES: 
There are no recommendations for use of zinc in symptomatic Wilson’s disease (WD). 
The aim was to study the clinical outcome of patients with symptomatic WD who were 
changed from penicillamine to zinc due to financial constraints or adverse effects. 
 
METHODS: 
All patients of patients of symptomatic hepatic +/- neurological/psychiatric 
manifestations of WD changed over from penicillamine to zinc sulfate and formed the 
study cohort. Diagnosis other than WD, atypical copper deposition disease and 
presymptomatic WD were excluded. Clinical and laboratory details at presentation, on 
penicillamine and on zinc were recorded. At each follow up visit and clinical worsening 
or improvement, compliance and adverse effects were recorded. The patients had 
periodic monitoring of hemoglobin, TC/DC, platelet count, liver function tests and 
prothrombin time. MELD and Nazer score and NWI were calculated at presentation, on 
penicillamine and on zinc. ANOVA was the statistical test used for comparing the means 
of variables at baseline, on penicillamine and on zinc therapy. 
 
RESULTS: 
28 patients formed the study cohort. 26 with pure hepatic manifestation, 2 with added 
neurological and 2 with added psychiatric manifestations. The mean age of subjects was 
17.5 ± 6.19 years. Mean duration of penicillamine therapy was 123.92 weeks (SD: 94.18; 
range: 2-320 weeks). The mean duration of zinc therapy was 175.92 weeks (SD: 122.82; 
range: 21 to 352 weeks). On follow up there was serial improvement in the serum 
bilirubin, serum albumin, PT INR, MELD score, Nazer score and Wilson disease 
prognostic index. Penicillamine is a good drug for initial chelation therapy for patients 
with symptomatic WD. Once switched over to zinc monotherapy these patients continue 
to remain compensated with maintenance or improvement of laboratory parameters 
and/or clinical scores. Penicillamine has serious and life threatening side effects where as 
zinc has minimal, tolerable and non life threatening side effects. Initial chelation with 
penicillamine followed by maintenance zinc monotherapy is an efficacious regime to 
treat symptomatic patients of hepatic Wilson’s disease. 
